IDEXX Laboratories, Inc. 是一家美国跨国公司,致力于为伴侣动物兽医、畜禽、水质检测和乳制品市场开发、制造和分销产品与服务。
财务指标
营业收入
2026-09-30
$12.14亿
2026-06-30
$12.16亿
2026-03-31
$11.4亿
2025-12-31
$10.9亿
营业支出
2026-09-30
$3.61亿
2026-06-30
$3.53亿
2026-03-31
$3.6亿
2025-12-31
$3.42亿
净利润
2026-09-30
$3.17亿
2026-06-30
$3.38亿
2026-03-31
$2.78亿
2025-12-31
$2.48亿
净利润率
2026-09-30
26.11%
2026-06-30
27.81%
2026-03-31
24.4%
2025-12-31
22.75%
每股收益
2026-09-30
$3.98
2026-06-30
$4.27
2026-03-31
$3.47
2025-12-31
$3.08
息税折旧摊销前利润
2026-09-30
$4.47亿
2026-06-30
$4.68亿
2026-03-31
$4亿
2025-12-31
$3.56亿
有效税率
2026-09-30
20.57%
2026-06-30
18.88%
2026-03-31
21.66%
2025-12-31
19.15%
项目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
营业收入
$12.14亿
$12.16亿
$11.4亿
$10.9亿
营业支出
$3.61亿
$3.53亿
$3.6亿
$3.42亿
净利润
$3.17亿
$3.38亿
$2.78亿
$2.48亿
净利润率
26.11%
27.81%
24.4%
22.75%
每股收益
$3.98
$4.27
$3.47
$3.08
息税折旧摊销前利润
$4.47亿
$4.68亿
$4亿
$3.56亿
有效税率
20.57%
18.88%
21.66%
19.15%
常见问题
IDXX is the ticker symbol for IDEXX Laboratories, Inc., a U.S. company whose shares trade on the Nasdaq Global Select Market. The stock represents an ownership stake in the business, meaning its value is tied to IDEXX's operating results, growth prospects, and overall market sentiment. IDXX is not an ETF or fund; it is a single operating company focused on products and services for veterinary diagnostics and related markets.
IDEXX Laboratories develops and sells diagnostic products, software, and services used mainly by veterinarians, livestock producers, and water-testing customers. Its offerings include in-clinic analyzers, reference laboratory services, rapid tests, practice-management software, and instruments for detecting contaminants in water. The companion animal segment is a major part of the business, supported by recurring revenue from consumables, service contracts, and diagnostic testing.
Recent performance depends on the latest market close, intraday moves, and the comparison period being used. Rather than rely on a stale figure, review the current IDXX quote, daily change, and longer-term price chart on this page. Those data points show how the stock has traded over days, weeks, months, and years. For context, compare IDXX with the broader market and its sector to see whether recent moves are company-specific or part of a wider trend.
Valuation can be assessed with metrics such as the price-to-earnings ratio, forward P/E, price-to-sales, price-to-book, and enterprise-value multiples. Comparing IDXX against its own historical ranges and against peers in diagnostics or medical technology helps frame whether the market is pricing in high growth expectations. Also review revenue growth, margins, free cash flow, and return on invested capital, since valuation multiples are only meaningful alongside the company's financial fundamentals.
IDEXX Laboratories historically has not paid a regular cash dividend, so IDXX is generally not considered an income-oriented stock. Instead, the company has retained earnings to fund growth initiatives, product development, acquisitions, and share repurchases when applicable. For the most accurate and current dividend status, including any special distributions or policy changes, check the dividend section of this IDXX page or the company's latest investor materials.
Key risks include competition from other veterinary diagnostics and software providers, dependence on clinic spending and pet-care demand, regulatory and reimbursement changes, product recalls or quality issues, foreign exchange fluctuations, and integration risks from acquisitions. Broader economic weakness could also reduce customer budgets. Because IDEXX operates globally, international market conditions, supply-chain disruptions, and changes in trade policy can affect results. Review the company's risk-factor disclosures for a fuller discussion.